tbuckley/cabot-search huggingface dataset:
Subgroup Analysis from a Phase 2 Study of the Efficacy and Safety of Parsaclisib, a Selective PI3Kδ Inhibitor, in Combination with Ruxolitinib in Patients with Myelofibrosis (MF)
Authors: Abdulraheem Yacoub, Uma Borate, Raajit Rampal, Haris Ali, Eunice S. Wang, Aaron T. Gerds, Gabriela Hobbs, Marina Kremyanskaya, Elliott Winton, Casey O'Connell, Swati Goel, Stephen Oh, Gary J. Schiller, Albert Assad, Sue Erickson-Viitanen, Feng Zhou, Naval Daver
Journal: Blood (2021)
Evaluation of International Working Group 2006 Response Criteria in Patients with Higher-Risk Myelodysplastic Syndromes (HR-MDS) Treated with Hypomethylating Agent Monotherapy in the Frontline Setting
Authors: Jan Philipp Bewersdorf, Wei Wei, Anna Jaiani, Prital Patel, Rajni Mehta, Natalia Neparidze, Rory M. Shallis, Nikolai Podoltsev, Andrew M. Brunner, Amer M. Zeidan
Journal: Blood (2021)
Chest Wall Analgesia—Where Do We Go From Here?
Authors: Kovi E. Bessoff, Ara Ko, Joseph D. Forrester
Journal: JAMA Network Open (2021)

Carlos E. Guerra-Londono, MD; Ann Privorotskiy, BA; Crispiana Cozowicz, MD; Rachel S. Hicklen, MS; Stavros G. Memtsoudis, MD, PhD, MBA; Edward R. Mariano, MD, MAS; Juan P. Cata, MD
Cytogenetics in Essential Thrombocythemia: Phenotype and Molecular Correlates and Prognostic Relevance in 818 Informative Cases
Authors: Naseema Gangat, Jaya Kittur, Yamna Jadoon, Natasha Szuber, Curtis A. Hanson, Alexandra P. Wolanskyj, Rhett P. Ketterling, Ayalew Tefferi
Journal: Blood (2021)
Concerns Remain Regarding Ambient NO<sub>2</sub> Exposure and the Risk of Parkinson Disease—Reply
Authors: Sungyang Jo, Ye-Jee Kim, Sun Ju Chung
Journal: JAMA Neurology (2021)

In Reply We appreciate Shi and colleagues for showing interest in our study1 demonstrating the association of nitrogen dioxide (NO2) and the incident risk of Parkinson disease (PD). They have suggested several methods for a more reliable exposure assessment of air pollutants.
HLA-Matched Related Hematopoietic Stem Cell Transplantation in Adolescents and Adults with Sickle Cell Disease: Comparison of Myeloablative Versus Non Myeloablative Approaches. Report from the Société Francophone De Greffe De Moelle Et De Thérapie Cellulaire
Authors: Nathalie Dhedin, Florian Chevillon, Martin Castelle, Virginie Lavoipierre, Jean-Hugues Dalle, Loïc Vasseur, Laure Joseph, Florence Beckerich, Nimrod Buchbinder, Tereza Coman, Frederic Garban, Alina Ferster, Nicolas Boissel, Stephanie Nguyen Quoc, Jean-Benoit Arlet, Corinne Pondarré
Journal: Blood (2021)
Vaccine Titers in Lymphoma Patients Receiving Chimeric Antigen Receptor T Cell Therapy
Authors: Radhika Bansal, Paschalis Vergidis, Pritish K Tosh, John Wilson, Matthew Hathcock, Arushi Khurana, N. Nora Bennani, Jonas Paludo, Jose C. Villasboas, Yucai Wang, Stephen M. Ansell, Patrick B. Johnston, Catherine Freeman, Yi Lin
Journal: Blood (2021)
A Phase I Study of CD19 Chimeric Antigen Receptor-T Cells Generated By the <i>PiggyBac</i> Transposon Vector for Acute Lymphoblastic Leukemia
Authors: Nobuhiro Nishio, Ryo Hanajiri, Yuichi Ishikawa, Makoto Murata, Rieko Taniguchi, Motoharu Hamada, Eri Nishikawa, Nozomu Kawashima, Atsushi Narita, Hideki Muramatsu, Yoshiyuki Takahashi
Journal: Blood (2021)
Efficacy of Avapritinib in Patients with Advanced Systemic Mastocytosis: Hematologic and Bone Marrow Responses from the Phase 2 Open-Label, Single-Arm, Pathfinder Study
Authors: Tracy I. George, Kristin H. Karner, Karen A. Moser, Anton Rets, Michelle Fredericks, Andreas Reiter, Deepti H. Radia, Michael W. Deininger, Hui-Min Lin, Jayita Sen, Jason Gotlib, Saša Dimitrijević, Daniel J. DeAngelo
Journal: Blood (2021)
An explainable artificial intelligence approach for decoding the enhancer histone modifications code and identification of novel enhancers in Drosophila
Authors: Jareth C. Wolfe, Liudmila A. Mikheeva, Hani Hagras, Nicolae Radu Zabet
Journal: Genome biology (2021)

Abstract Background Enhancers are non-coding regions of the genome that control the activity of target genes. Recent efforts to identify active enhancers experimentally and in silico have proven effective. While these tools can predict the locations of enhancers with a high degree of accuracy, the mechanisms underpinning the activity of enhancers are often unclear. Results Using machine learning (ML) and a rule-based explainable artificial intelligence (XAI) model, we demonstrate that we can predict the location of known enhancers in Drosophila with a high degree of accuracy. Most importantly, we use the rules of the XAI model to provide insight into the underlying combinatorial histone modifications code of enhancers. In addition, we identified a large set of putative enhancers that display the same epigenetic signature as enhancers identified experimentally. These putative enhancers are enriched in nascent transcription, divergent transcription and have 3D contacts with promoters of transcribed genes. However, they display only intermediary enrichment of mediator and cohesin complexes compared to previously characterised active enhancers. We also found that 10–15% of the predicted enhancers display similar characteristics to super enhancers observed in other species. Conclusions Here, we applied an explainable AI model to predict enhancers with high accuracy. Most importantly, we identified that different combinations of epigenetic marks characterise different groups of enhancers. Finally, we discovered a large set of putative enhancers which display similar characteristics with previously characterised active enhancers.
Safety and Efficacy from a Phase 1b/2 Study of IMGN632 in Combination with Azacitidine and Venetoclax for Patients with CD123-Positive Acute Myeloid Leukemia
Authors: Naval Daver, Ahmed Aribi, Pau Montesinos, Gail J. Roboz, Eunice S. Wang, Roland B. Walter, Deepa Jeyakumar, Daniel J. DeAngelo, Harry P. Erba, Anjali Advani, Patrick W. Burke, Giovanni Martinelli, Lauris Gastaud, Xavier Thomas, Jessica K. Altman, Lourdes M. Mendez, Adolfo de la Fuente, Elisabetta Todisco, Gianluca Gaidano, Antonio Curti, Nicolas Boissel, Christian Recher, Christoph Schliemann, Marina Konopleva, David A. Sallman, Laura Torres, Guido Marcucci, Hagop Kantarjian, Callum M Sloss, Kara E Malcolm, Patrick A Zweidler-McKay, Kendra Sweet
Journal: Blood (2021)
Multi-scale semi-supervised clustering of brain images: Deriving disease subtypes
Authors: Junhao Wen, Erdem Varol, Aristeidis Sotiras, Zhijian Yang, Ganesh B. Chand, Guray Erus, Haochang Shou, Ahmed Abdulkadir, Gyujoon Hwang, Dominic B. Dwyer, Alessandro Pigoni, Paola Dazzan, Rene S. Kahn, Hugo G. Schnack, Marcus V. Zanetti, Eva Meisenzahl, Geraldo F. Busatto, Benedicto Crespo-Facorro, Romero-Garcia Rafael, Christos Pantelis, Stephen J. Wood, Chuanjun Zhuo, Russell T. Shinohara, Yong Fan, Ruben C. Gur, Raquel E. Gur, Theodore D. Satterthwaite, Nikolaos Koutsouleris, Daniel H. Wolf, Christos Davatzikos
Journal: Medical Image Analysis (2021)
Age, Sex and Self-Reported Race Differences in Immune Profiles of Hematologic Malignancy Patients
Authors: Megan M. Herr, Paul K. Wallace, Yali Zhang, George L. Chen, Sophia R. Balderman, Maureen Ross, Christine Ho, Jens Hillengass, Eunice S. Wang, Amanda Przespolewski, Elizabeth A. Griffiths, Pallawi Torka, Francisco J. Hernandez-Ilizaliturri, Paola Ghione, Philip L. McCarthy, Theresa E. Hahn
Journal: Blood (2021)
Clonal Hematopoiesis in Telomere Biology Disorders Associates with the Underlying Germline Defect and Somatic Mutations in <i>POT1</i>, <i>PPM1D,</i> and <i> TERT</i> promoter
Authors: Fernanda Gutierrez-Rodrigues, Emma M Groarke, Diego V Clé, Bhavisha A. Patel, Flávia S Donaires, Nina Spitofsky, Lemlem Alemu, Bárbara A Santana, Sachiko Kajigaya, Simona Colla, Michel Michels De Oliveira, Carmem M. S. Bonfim, Rodrigo T. Calado, Neal S. Young
Journal: Blood (2021)
Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma
Authors: Sagar Lonial, Stefano R. Tarantolo, Ralph V. Boccia, Habte Yimer, Moshe Y. Levy, Rafat Abonour, Meera Mohan, Vivek Roy, Jeremy T. Larsen, Saulius K. Girnius, Cara A. Rosenbaum, Omar Nadeem, Deborah Berg, Bo Chao, Allison J Berger, Akito Nakamura, Yuhong Zhang, Keli Song, Christine K. Ward, Igor Proscurshim, Shaji Kumar
Journal: Blood (2021)
CD22 CAR Optimization for Improved in-Human Activity Following Inadequate CD22 CAR Activity in Phase 1 Clinical Trial PLAT-04
Authors: Corinne Summers, Blake Baxter, Colleen Annesley, Jason Yokoyama, Stephanie Rhea, Wenjun Huang, Ashley Wilson, Julie R. Park, Rimas J Orentas, Michael C. Jensen, Rebecca A Gardner
Journal: Blood (2021)
Combinatorial Genetic Uncovers <i>DOCK1/RAC2</i> As Specific Targets for the Treatment of <i> NPM1;Cohesin</i> Mutated AML
Authors: Alison E Meyer, Cary Stelloh, Kirthi Pulakanti, Robert Burns, Joseph B Fisher, Katelyn E Heimbruch, Sergey Tarima, Aaron D Viny, George S. Vassiliou, Sridhar Rao
Journal: Blood (2021)
CSIG-32. microRNA 211, A POTENTIAL THERAPEUTIC AGENT FOR GROUP 3 MEDULLOBLASTOMA IN CHILDREN
Authors: Keisuke Katsushima, Bongyong Lee, Menglang Yuan, Haritha Kunhiraman, Stacie Stapleton, George Jallo, Eric Raabe, Charles Eberhart, Ranjan Perera
Journal: Neuro-Oncology (2021)

Abstract Medulloblastoma (MB) is a central nervous system (CNS) tumor that predominantly affects children and requires aggressive therapy. Affected individuals often suffer from treatment-related side-effects and treatment-resistant recurrences associated with high morbidity and mortality rates. There are four major molecular MB subgroups: wingless-type (Wnt)-activated, sonic hedgehog (Shh)-activated, group III (G3), and group IV (G4) MBs. While the molecular pathology of Wnt- and Shh-activated MBs is well defined, rather less is known about G3 and G4 MB's genetic basis, so their molecular diagnosis and consequent management have remained challenging. MBs develop through various genetic, epigenetic, and non-coding (nc)RNA-related mechanisms, with the role of ncRNAs, particularly microRNAs, in MB tumor growth is poorly defined. We addressed this knowledge gap with an exemplar of microRNA-211 (miR-211) implicated in G3 MB tumor growth. Compared to other MB subgroups, miR-211 is significantly downregulated in G3 MB cell lines, underscoring its important role as a therapeutic agent and a biomarker. miR-211 overexpression in G3 MB cells significantly reduced cell proliferation, invasion, 3D colony formation, and induced apoptosis. Oxygen consumption rates are higher in engineered cells, and we postulate that miR-211 is involved in G3 MB mitochondrial energy metabolism. miR-211 expressed G3 MB cells injected into mouse cerebella produce smaller tumors than those derived from parental cells. We applied single-cell RNA sequencing and immune histochemical assays to characterize tumors to identify the molecular mechanism of miR-211- driven tumor reduction in G3 MBs, and our preliminary results support that miR-211 is an attractive therapeutic agent to treat this aggressive MB subtype.
A Phase 1/2 Study of Single Agent Tagraxofusp, a First-in-Class CD123-Targeted Therapy, in Patients with Myelofibrosis That Is Relapsed/Refractory Following JAK Inhibitor Therapy
Authors: Abdulraheem Yacoub, Mrinal M. Patnaik, Haris Ali, Eunice S. Wang, Vikas Gupta, Sangmin Lee, Gary J. Schiller, Minakshi S. Taparia, Animesh Pardanani, Ayalew Tefferi, Srdan Verstovsek, Joseph D. Khoury, Christopher L Brooks, Tariq I. Mughal, Naveen Pemmaraju
Journal: Blood (2021)
The 1.5 Million Platelet Count Threshold in Essential Thrombocythemia: Phenotype and Genotype Correlates and Relevance to Vascular Events
Authors: Naseema Gangat, Natasha Szuber, Yamna Jadoon, Faiqa Farrukh, Elena Rossi, Francesco Ramundo, Curtis A. Hanson, Alexandra P. Wolanskyj, Animesh D. Pardanani, Valerio De Stefano, Alessandro M. Vannucchi, Tiziano Barbui, Ayalew Tefferi
Journal: Blood (2021)
Outcomes with Natural Killer Cells Infusion after Allogeneic Hematopoietic Stem Cell Transplantation: A Systematic Review and Meta-Analysis
Authors: Muhammad Umair Mushtaq, Moazzam Shahzad, Amna Y Shah, Muhammad Usman Zafar, Ezza Tariq, Anam Hamid, Ayna Serwat, Iqra Anwar, Sibgha Gull Chaudhary, Nausheen Ahmed, Sunil Abhyankar, Natalie S. Callander, Peiman Hematti, Joseph P. McGuirk
Journal: Blood (2021)
COVID-19 Vaccine Boosters for All Adults: An Optimal U.S. Approach?
Authors: Ameet Sarpatwari, Ankur Pandya, Emily P. Hyle, Govind Persad
Journal: Annals of Internal Medicine (2021)

October 2021, the U.S. Food and Drug Administration (FDA) had amended its Emergency Use Authorizations for immunocompetent adults who previously received the Pfizer-BioNTech, Moderna, or Johnson & Johnson COVID-19 vaccines.For the 2-dose Pfizer-BioNTech and Moderna vaccines, the FDA permitted a single booster dose for adults aged 65 years or older and adults aged 18 to 64 years at high-risk for severe COVID-19 or at high risk for occupational or institutional COVID-19 exposure.For the single-dose Johnson & Johnson vaccine, the FDA permitted a single booster dose for all adults aged 18 or older.These eligibility schemes were endorsed by the Centers for Disease Control and Prevention shortly after FDA approval.The Biden administration, meanwhile, has pledged that boosters will soon be available for all adults (1).Many experts have criticized boosters for unfairly drawing on the global vaccine supply when many countries have not yet been able to vaccinate even a tenth of their population.However, when compared with other uses of the same resources, will a U.S. booster-for-all policy be detrimental not only to the global community, but also for Americans?Answering this question requires estimating the relevant consequences of the policy relative to plausible alternative policies.Data regarding the benefits and harms of boosters remain preliminary and limited.Although benefits include
Abstract 10709: Findings on Cardiology Screening Parameters for Cardiac Amyloidosis Differ Between African American and Non-African American Patients
Authors: Sonakshi Manjunath, Elena Deych, Daniel Lenihan, Kathleen Zhang
Journal: Circulation (2021)

Introduction: Prior studies have shown worse outcomes for African American (AA) patients with cardiac amyloidosis as compared to Caucasians. A potential contribution of diagnostic bias to delayed diagnosis of cardiac amyloidosis in AAs has not previously been explored. Hypothesis: Standard screening parameters for cardiac amyloidosis have worse diagnostic accuracy in AA as compared to non-AA patients. Methods: Patients evaluated at our institution from 2000-2018 for suspected cardiac amyloidosis with diagnostic confirmation by cardiac biopsy were included. Demographic, clinical and laboratory parameters at the time of evaluation were obtained, and ECGs and echocardiograms were analyzed by study personnel. Each parameter was compared between the biopsy positive and biopsy negative groups separately for AA and non-AA patients. Results: Among 223 patients with suspected cardiac amyloidosis, 90 were AA (64% biopsy positive) and 133 were non-AA (51% biopsy positive). Older age, low limb lead voltage, increased relative wall thickness, and apical sparing of longitudinal strain were associated with a positive biopsy in both AAs and non-AAs. Male gender, pseudoinfarct pattern, higher E/e’, and lower voltage-to-mass ratio were associated with a positive biopsy in non-AAs (p&lt;0.05), but not in AAs. This is displayed in the figure below. Brain natriuretic peptide level and left ventricular mass index were higher in the biopsy positive patients among non-AAs, and lower in the biopsy positive patients among AAs. Conclusions: Several traditional screening parameters for cardiac amyloidosis were not discerning for the diagnosis among AAs who underwent cardiac biopsy for evaluation. The development of cardiac amyloidosis screening tools tailored to AA patients may improve clinical outcomes for AAs with cardiac amyloidosis.
Efficient Screening Tests and Gene Mutation Spectrum for Hereditary Stomatocytosis in Japan
Authors: Erina Nakahara, Keiko Yamamoto, Takako Aoki, Hiromi Ogura, Taiju Utsugisawa, Hiroyuki Akagawa, Toshiyuki Yamamoto, Yoshiro Maru, Fumihiko Nakamura, Hiroshi Yagasaki, Etsuro Ito, Shouichi Ohga, Hitoshi Kanno
Journal: Blood (2021)
Severe delayed hypersensitivity reactions to IL-1 and IL-6 inhibitors link to common HLA-DRB1*15 alleles
Authors: Vivian E Saper, Michael J Ombrello, Adriana H Tremoulet, Gonzalo Montero-Martin, Sampath Prahalad, Scott Canna, Chisato Shimizu, Gail Deutsch, Serena Y Tan, Elaine F Remmers, Dimitri Monos, Timothy Hahn, Omkar K Phadke, Elaine Cassidy, Ian Ferguson, Vamsee Mallajosyula, Jianpeng Xu, Jaime S Rosa Duque, Gilbert T Chua, Debopam Ghosh, Ann Marie Szymanski, Danielle Rubin, Jane C Burns, Lu Tian, Marcelo A Fernandez-Vina, Elizabeth D Mellins, Jill A Hollenbach
Journal: Annals of the Rheumatic Diseases (2021)

Drug reaction with eosinophilia and systemic symptoms (DRESS) is a severe, delayed hypersensitivity reaction (DHR). We observed DRESS to inhibitors of interleukin 1 (IL-1) or IL-6 in a small group of patients with Still's disease with atypical lung disease. We sought to characterise features of patients with Still's disease with DRESS compared with drug-tolerant Still's controls. We analysed human leucocyte antigen (HLA) alleles for association to inhibitor-related DHR, including in a small Kawasaki disease (KD) cohort.
Covid-19 and laws for workplace violence in healthcare
Authors: Mahesh Devnani
Journal: BMJ (2021)

Workplace violence in the healthcare sector is increasingly being acknowledged worldwide as a serious occupational health hazard requiring urgent preventive measures.1 Workplace violence is defined as situations in which staff are ill treated, intimidated, or attacked in conditions linked to their workplace (including commuting to and from the workplace), involving an explicit or implicit challenge to their safety, wellbeing, or health. The World Health Organization reports that between 8% …
Caplacizumab Is Effective in Treating Immune-Mediated Thrombotic Thrombocytopenic Purpura in Real-World Scenarios and May Lower Mortality: An Aggregative Analysis
Authors: Linus A. Völker, Gesa Balduin, Lucas Kühne, Jessica Kaufeld, Ulf Schönermarck, Jan Menne, Paul Knöbl, Paul Brinkkoetter
Journal: Blood (2021)
Decrease in early mortality for newly diagnosed multiple myeloma patients in the Netherlands: a population-based study
Authors: Mirian Brink, Kaz Groen, Pieter Sonneveld, Monique C. Minnema, Annemiek Broijl, Avinash G. Dinmohamed, Ellen van der Spek, Mark-David Levin, Paula F. Ypma, Esther de Waal, Eduardus F. M. Ward Posthuma, Sonja Zweegman, Niels W. C. J. van de Donk
Journal: Blood Cancer Journal (2021)

Identification of risk factors for early mortality (EM) in multiple myeloma (MM) patients may contribute to different therapeutic approaches in patients at risk for EM. This population-based study aimed to assess trends in EM and risk factors for EM among MM patients diagnosed in the Netherlands. All MM patients, newly diagnosed between 1989 and 2018, were identified in the Netherlands Cancer Registry. Patients were categorized into three calendar periods (1989-1998, 1999-2008, 2009-2018) and into five age groups (≤65, 66-70, 71-75, 76-80, >80 years). EM was defined as death by any cause ≤180 days post-diagnosis. We included 28,328 MM patients (median age 70 years; 55% males). EM decreased from 22% for patients diagnosed in 1989-1998 to 13% for patients diagnosed in 2009-2018 (P < 0.01) and this decrease was observed among all age groups. Exact causes of death could not be elucidated. Besides patient's age, we found that features related to a more aggressive disease presentation, and patient characteristics reflecting patients' physical condition were predictive of EM. In summary, EM decreased from 1999 onwards. Nevertheless, EM remains high, especially for patients aged >70 years. Therefore, novel strategies should be explored to improve the outcome of patients at risk for EM.
Efficacy and Safety of Selinexor-Containing Regimens in Patients with Multiple Myeloma Previously Treated with Anti-CD38 Monoclonal Antibodies (αCD38 mAb)
Authors: Suzanne Lentzsch, Brea Lipe, Sascha A. Tuchman, Nizar J. Bahlis, William I. Bensinger, Michael Sebag, Heather J. Sutherland, Jorge Monge, Cristina J. Gasparetto, Muhamed Baljevic, Natalie S. Callander, Christopher P. Venner, Darrell J. White, Rami Kotb, Christine I. Chen, Gary J. Schiller, Sumit Madan, Richard Leblanc, Andrew DeCastro, Ohad S. Bentur, Jatin J. Shah, Dane R. Van Domelen, Michael G. Kauffman, Sharon Shacham, Noa Biran
Journal: Blood (2021)
Frequency and Duration of Boarding for Pediatric Mental Health Conditions at Acute Care Hospitals in the US
Authors: JoAnna K. Leyenaar, Seneca D. Freyleue, Amy Bordogna, Christopher Wong, Nicole Penwill, Ryan Bode
Journal: JAMA (2021)

This study estimates the frequency and duration of boarding for pediatric mental health conditions at US acute care hospitals and describes hospital resources available to support youths during boarding.
Histone Acetyltransferase (HAT) Activator, YF2, Modulates the p53:BCL6 Axis and Antigen Presentation in Diffuse Large B-Cell Lymphomas
Authors: Brian Estrella, Yuxuan Liu, Edd C Ricker, Manuel A Pazos, Jole Fiorito, Elisa Zuccarello, Elisa Calcagno, Barry Honig, Ottavio Arancio, Jennifer E. Amengual
Journal: Blood (2021)
Abstract 14587: Electrocardiogram Findings Amongst Latin American Immigrants at Risk for Chagas Disease in Florida
Authors: Omkar Betageri, Joshua Latner, Laura Velez, Austin White, Paola Trejo, Rodrigo Alcala, Nelson Duque, Maria Carrasquilla, Rhoel Dinglasan, Vilma Torres, Norman Beatty
Journal: Circulation (2021)

Introduction: Chagas disease (CD) is caused by the parasite Trypanosoma cruzi and can lead to chronic Chagas cardiomyopathy (CCC). Cardiac arrhythmias are common in CCC and include AV node pathology, intraventricular conduction disease, ventricular arrhythmias, and other abnormalities. In the U.S. there are at least 300,000 immigrants from Latin America living with CD, but it is estimated that only 1% have been diagnosed. Florida is suspected to carry the third highest burden with approximately 18,000 people living with CD. Hypothesis: The purpose of this study is to investigate the prevalence of electrocardiogram (ECG) findings amongst a Hispanic immigrant population at risk for CCC in Florida. Methods: Latin American immigrants who were either born or lived in endemic regions and now reside in Florida were enrolled in the study after informed consent. All participants completed an epidemiological survey, underwent 12-lead ECG testing, and provided a fingerstick and venous blood sample for further CD testing. ECGs were interpreted by a board-certified electrophysiologist. Results: A total of 151 individuals were enrolled with a mean age of 44 years and 58.9% being female. The most common countries of origin were Venezuela (34.4%), Mexico (18.5%), Honduras (12.6%), and Colombia (11.9%). Overall, 7.3% had an intraventricular conduction delay (LBBB 0.7% , RBBB 2.0%, LAFB 2.0%, and other IVCD 2.6%). A 1st degree AV block was found in 0.7% and no participants had a higher degree AV block. Ischemic changes were noted in 15.9% of participants, with infarct pattern in 3.3% and non-specific ST-T wave changes in 13.2%. Rhythm findings included normal sinus rhythm 77.5%, sinus bradycardia 21.2%, atrial fibrillation 0.7%, and ectopic atrial rhythm 0.7%. Other findings included borderline prolonged QTc 1.3%, prolonged QTc 2.0%, PACs 1.3% and no patients with PVCs. Conclusions: Review of this preliminary data shows a significant number of ECG abnormalities among this cohort of Latin American immigrants in Florida which can be associated with CD and CCC. Of particular interest is the high prevalence of sinus bradycardia as compared to prior population studies. A full comparative analysis of ECG findings amongst those who test positive for CD in this cohort is ongoing.